Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

SummaryBackground Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatoryactions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19.Methods In this randomised, controlled, open-label, adaptive platform trial (Randomised Evaluation of COVID-19Therapy [RECOVERY]), several possible treatments were compared with usual care in patients admitted to hospitalwith COVID-19 in the UK. The trial is underway at 176 hospitals in the UK. Eligible and consenting patients wererandomly allocated to either usual standard of care alone or usual standard of care plus azithromycin 500 mg once perday by mouth or intravenously for 10 days or until discharge (or allocation to one of the other RECOVERY treatmentgroups). Patients were assigned via web-based simple (unstratified) randomisation with allocation concealment andwere twice as likely to be randomly assigned to usual care than to any of the active treatment groups. Participants andlocal study staff were not masked to the allocated treatment, but all others involved in the trial were masked to theoutcome data during the trial. The primary outcome was 28-day all-cause mortality, assessed in the intention-to-treatpopulation. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936.Findings Between April 7 and Nov 27, 2020, of 16 442 patients enrolled in the RECOVERY trial, 9433 (57%) wereeligible and 7763 were included in the assessment of azithromycin. The mean age of these study participants was65·3 years (SD 15·7) and approximately a third were women (2944 [38%] of 7763). 2582 patients were randomlyallocated to receive azithromycin and 5181 patients were randomly allocated to usual care alone. Overall,561 (22%) patients allocated to azithromycin and 1162 (22%) patients allocated to usual care died within 28 days(rate ratio 0·97, 95% CI 0·87–1·07; p=0·50). No significant difference was seen in duration of hospital stay (median10 days [IQR 5 to >28] vs 11 days [5 to >28]) or the proportion of patients discharged from hospital alive within 28 days(rate ratio 1·04, 95% CI 0·98–1·10; p=0·19). Among those not on invasive mechanical ventilation at baseline, nosignificant difference was seen in the proportion meeting the composite endpoint of invasive mechanical ventilationor death (risk ratio 0·95, 95% CI 0·87–1·03; p=0·24).Interpretation In patients admitted to hospital with COVID-19, azithromycin did not improve survival or otherprespecified clinical outcomes. Azithromycin use in patients admitted to hospital with COVID-19 should be restrictedto patients in whom there is a clear antimicrobial indication

kimberscott/lookit-data-processing: Coding functionality compatible with lookit-api (Lookit/Experimenter v2)

Analysis and video processing scripts for Lookit dat

StarT-ng: Delivering Seamless Parallel Computing

StarT-ng is a joint MIT-Motorola project to build a high-performance message passing machine from commercial systems. Each site of the machine consists of a PowerPC 620-based Motorola symmetric multiprocessor (SMP) running the AIX 4.1 operating system. Every processor is connected to a low-latency, high-bandwidth network that is directly accessible from user-level code. In addition to fast message passing capabilities, the machine has experimental support for cache-coherent shared memory across sites. When the machine requires memory to be kept globally coherent, one processor on each site is devoted to supporting shared memory. When globally coherent shared memory is not required, that processor can be used for normal computation tasks. StarT-ng will be delivered at about the time the base SMP is introduced into the marketplace. The ability to be both a collection of standard SMP and an aggressive message passing machine with coherent shared memory makes StarT-ng a good building block..

Software Carpentry: Programming with GAP

A half-day introduction to programming in the computational algebra system GAP (http://www.gap-system.org/), developed and maintained by Alexander Konovalov. The template for the Software Carpentry lesson is developed and maintained by the Software Carpentry team

Software Carpentry: Automation and Make

A half-day introduction to task automation with Make, developed and maintained by the Software Carpentry team

Software Carpentry: Programming with MATLAB

A half-day introduction to programming in MATLAB for researchers, developed and maintained by the Software Carpentry team

swcarpentry/instructor-training: Software Carpentry: Instructor Training

A two-day introduction to modern evidence-based teaching practices, built and maintained by the Carpentry community

alex-konovalov/gap-lesson: aachen2018

GAP Software Carpentry Lesso

Software Carpentry: Version Control with Git

A half-day introduction to version control with Git and GitHub for researchers, developed and maintained by the Software Carpentry team